The Golden Age of Chinese Biopharma Sector, 2014–2021: Explosive Growth in a Thriving Ecosystem

Sven Agten () and Ben Wu ()

A chapter in Biopharma in China, 2024, pp 41-69 from Springer

Abstract: Abstract The Chinese biopharma sector has witnessed an unprecedented growth, referred to as the ‘Golden Age’. A combination of factors has nurtured this explosive domestic growth in the pharma and biotech space. With the largest population in the world and with little access to the latest innovative medicines, China provided huge market opportunities. Regulatory reforms made approval of new drugs much easier, which led to venture capitalists eying the Chinese biopharma sector as new growth sector. The government streamlined the clinical trial and drug approval process, including priority and special reviews as well as breakthrough therapy designations for innovative products that target unmet medical needs in China. The NRDL is also being updated more frequently and prioritizes the entry of newly approved novel drugs. Then there is also the huge number of hospitals which provide a massive set of potential patients to enroll into clinical trials. New capital sources became available, when in 2018 changes in policy allowed pre-revenue/pre-profit biotech companies to be listed in the Hong Kong Stock Exchange (HKEX) or Shanghai Stock Exchange’s Science and Technology Innovative Board (STAR). Combined together, all of these factors can be seen as the rocket booster for growth, which fueled the Golden Age of the Chinese biopharma sector.

Keywords: Venture capital (VC); Biotechnology; Clinical trials; Contract research organization (CRO); Contract development and manufacturing organization (CDMO); Hong Kong Stock Exchange (HKEX); In-licensing; Research & Development (R&D); Sea turtles; Shanghai Stock Exchange’s Science and Technology Innovative Board (STAR) (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-97-1471-1_3

Ordering information: This item can be ordered from
http://www.springer.com/9789819714711

DOI: 10.1007/978-981-97-1471-1_3

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().